Tenax Therapeutics (TENX) Free Cash Flow (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Free Cash Flow of -$14.2 million for Q2 2026, down 127.78% year-over-year from $51.1 million in Q2 2025, and down 52.44% on a QoQ basis from -$9.3 million in Q1 2026.
Tenax Therapeutics (TENX) Free Cash Flow (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$14.2 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at -$14.2 million, down 127.78% year-over-year; the trailing twelve-month figure through Jun 2026 was -$46.1 million (down 132.2% YoY), and the FY2025 annual result was -$35.8 million, down 141.71% from the prior year.
- Free Cash Flow declined to -$14.2 million in Q2 2026, from -$9.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$924568.0 in Q2 2023 and troughed at -$14.2 million in Q2 2026.
- A 5-year average of -$5.1 million and a median of -$3.4 million in 2022 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2023, when Free Cash Flow surged 73.05%; it then plunged 281.66% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$1.7 million in 2022, then soared by 30.26% to -$1.2 million in 2023, then tumbled by 198.81% to -$3.5 million in 2024, then plunged by 281.66% to -$13.4 million in 2025, then declined by 5.9% to -$14.2 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$14.2 million in Q2 2026, -$9.3 million in Q1 2026, and -$13.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | -14.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.19 Mn |
| Jun 30, 2026 | -14.19 Mn |
| Mar 31, 2026 | -9.31 Mn |
| Mar 31, 2026 | -9.31 Mn |
| Dec 31, 2025 | -13.40 Mn |
| Dec 31, 2025 | -13.40 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Jun 30, 2025 | -6.23 Mn |
| Jun 30, 2025 | -6.23 Mn |
| Mar 31, 2025 | -7.00 Mn |
| Mar 31, 2025 | -7.00 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -3.10 Mn |
| Sep 30, 2024 | -3.10 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | -5.17 Mn |
| Mar 31, 2024 | -5.17 Mn |